Humacyte (HUMA) Assets Average (2020 - 2026)

Humacyte (HUMA) has reported Assets Average for 7 consecutive years, with $124.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 17.49% year-over-year to $124.3 million in Q2 2026; TTM through Jun 2026 was $124.3 million, a 17.49% decrease from a year earlier, with the FY2025 full-year figure at $127.1 million, down 4.46% from the prior year.
• Assets Average was $124.3 million for Q2 2026 at Humacyte, up from $113.5 million in the prior quarter.
• Over five years, Assets Average peaked at $275.5 million in Q1 2022 and troughed at $103.9 million in Q4 2025.
• A 5-year average of $164.1 million and a median of $150.0 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 165.73% in 2022 and plunged 35.52% in 2023, its largest moves.
• Over 5 years, Assets Average stood at $215.3 million in 2022, then sank by 35.52% to $138.8 million in 2023, then declined by 9.0% to $126.3 million in 2024, then fell by 17.72% to $103.9 million in 2025, then grew by 19.61% to $124.3 million in 2026.
• The last three Assets Average figures came in at $124.3 million (Q2 2026), $113.5 million (Q1 2026), and $103.9 million (Q4 2025), per Business Quant data.